Revolo Biotherapeutics

In this article by Jo Shorthouse of @Citeline’s In Vivo, our CSO Roly Foulkes, PhD, discusses how our lead oral investigational treatment works to promote immune tolerance for the treatment of inflammatory diseases like eosinophilic esophagitis. Read here: bit.ly/4m7IHdg

Today, we announced that based on new positive preclinical data, we will accelerate the development of our lead investigational treatment, ‘1104, in an orally administered form, with plans to enter the clinic in 2026. Read more: bit.ly/453nps7

Last week, our Chief Medical Officer, Kari Brown, MD, had the honor of participating in a panel discussion at #BIO2025. She discussed the evolution of the Immunology & Inflammation (I&I) – a market poised for significant growth – and Revolo’s differentiated approach.

If you are attending #BIO2025, don’t miss a panel on Thursday on I&I innovation, featuring our Chief Medical Officer, Kari Brown, MD, and other industry leaders. Learn more about the panel and add it to your calendar here: bit.ly/3FPaT5S

During #ClinicalTrialsDay last week, our Chief Medical Officer, Kari Brown, MD, was featured by Clinical Leader discussing our work to make our lead allergic disease candidate patient friendly. Read the article here: bit.ly/4jrZRB4

Today is #EoEDay. Eosinophilic esophagitis (EoE) is a chronic allergic disease that is characterized by inflammation of the esophagus. At Revolo, we aim to raise awareness for EoE, current treatments, and therapeutic innovations. Learn more: bit.ly/3Fhn3Ek

Our VP of Discovery and Translational Science, Dr. Jorge De Alba, presented a poster at @atscommunity’s #ATS2025 on the potential of our lead candidate as an oral tablet to provide a long-lasting effect for a wide spectrum of #AllergicDiseases. View here: bit.ly/4k5WT6A

Members of our leadership team connected with Tom von Gunden for his “In Combination” series with Drug Delivery Leader. They discussed the advancement of our investigational treatment for #AllergicDiseases in patient-friendly formulations. Watch here: bit.ly/3S9q6Ru

Our Chief Scientific Officer, Dr. Roly Foulkes, will present at the 7th Treg-Directed Therapies Summit in Boston. Check out the event agenda to learn more ahead of his presentation on the potential of our lead candidate for #AllergicDiseases: bit.ly/4hMWUdu

Our CEO, Woody Bryan, PhD, recently connected with @dslevine for an episode of The Bio Report podcast. Listen to the episode linked below to learn more about our lead investigational treatment for #AllergicDiseases including #EosinophilicEsophagitis and #AtopicDermatitis.

Dr. Jorge De Alba, VP, Discovery and Translational Science, presented two posters on our lead #AllergicDisease candidate at #AAAAI25, showcasing its potential to be formulated for multiple routes of administration. Check out the posters here: bit.ly/3QNr7OG

Our CEO, Woody Bryan, PhD, provided commentary on what to watch in 2025 for @PharmaScrip’s Scrip Asks series. As we continue to advance our #AllergicDisease candidate, we expect to see continued growth and investment in the space. Read more: bit.ly/3XbMvRm

Later this month, our Vice President, Discovery and Translational Science, Dr. Jorge De Alba, will present data for our lead #AllergicDisease candidate, ‘1104, at #AAAAI25. Learn more about our posters by reading our press release: bit.ly/418vfP6

Our CEO, Woody Bryan, PhD, and CMO, Kari Brown, MD, recently connected with @ctrialvanguard. Read the article for more on the clinical data for our lead candidate and our plans for new studies in eosinophilic esophagitis (EoE) and other allergic diseases: clinicaltrialvanguard.com/executiveinter…

Don’t miss us at #JPM2025! Members of our executive leadership team including our President and CEO, Woody Bryan, and CFO, Jonathan Gold, will be in San Francisco. If interested in a meeting, reach out via our website: bit.ly/4goAhfy #JPM25

We are excited to share new preclinical data supporting the subcutaneous administration of our lead allergic disease drug candidate for #AtopicDermatitis and other clinical programs. Learn more in our press release here: bit.ly/3Dou7xi

Our CEO, Woody Bryan, PhD, recently connected with Matt Pillar, host of @BioProcessOL's #BusinessOfBiotech podcast. Listen to hear what we are doing to deliver ‘1104, our lead candidate for #AllergicDiseases, in forms that are most convenient for patients: bit.ly/3Zipv3m

Are you attending the Autoimmunity Pharma & Biotech Partnering Summit in Boston? Don’t miss our Chief Scientific Officer, Roly Foulkes, PhD, present on the clinical potential of our lead candidate for #AllergicDiseases. Learn more: autoimmunity-partnering.com

In addition to the data for the subcutaneous injection form of our lead drug candidate for #AllergicDiseases including #EosinophilicEsophagitis and #AtopicDermatitis, new preclinical results show its potential for sublingual administration. Learn more: bit.ly/3YvcnbH

Today we shared new preclinical data that validates #AtopicDermatitis as an additional target indication for our lead allergic disease drug candidate that acts upstream in the immune system cascade. Read our press release to learn more: bit.ly/3XNRWGU